Technavio, a tech-focused market research firm, has published a new report on the global ENT disorder treatment market, which is expected to grow at a CAGR of more than 2% during the forecast period 2017-2021.
Based on geographical segmentation, Technavio market researchers categorize the global ENT disorder treatment market into the following key regions: the Americas, APAC, and EMEA.
Source: Technavio
Click here to request a free sample of this report
Top three contributors for the global ENT disorder treatment market are elaborated below:
ENT disorder treatment market in the Americas: Driven by the high prevalence of diseases such as rhinitis and sinusitis in the country, the US accounts for a majority of the revenue generated by the ENT disorder treatment market in the Americas. As per CDC reports, approximately 8% of the US population was diagnosed with allergic rhinitis during 2014. Some of the most common types of allergies in the region are pollen from grass and weed, dust mites, mold spores, cockroaches, dog, cat, and rodent dander. According to Technavio’s market research analysts, the ENT disorder treatment market in the Americas is projected to register growth at a CAGR of almost 2% between 2017 and 2021.
According to Barath Palada, a lead analyst at Technavio, specializing in research on cardiovascular and metabolic disorders, “The ENT disorder treatment market is saturated in developed countries such as the US. However, developing economies in the region such as Mexico and Brazil have immense potential for growth and are expected to drive growth of the ENT disorder treatment market in the Americas during the forecast period.”
ENT disorder treatment market in EMEA: The growing prevalence of ENT disorders, especially allergic disorders, coupled with an established healthcare infrastructure in Europe are some of the key factors driving the demand for ENT disorder treatments, particularly for allergic rhinitis, in EMEA. Growing urbanization, pollution, climate change, and industrialization are expected to further aggravate the problem. Various steps have been taken by both governmental and non-governmental bodies to handle the situation, such as, the Finish allergy program, which aims at uniting NGOs and healthcare professionals to control allergic outbreaks in the region. In addition, organizations such as the European Academy of Allergy and Clinical Immunology (EAACI) are working toward the allocation of funds for research on allergies in the European countries, which in turn, will favor growth of the market.
ENT disorder treatment market in APAC: The untapped potential of APAC countries is expected to be a major driver for market growth. Countries such as India and China are going through huge urbanization, resulting in higher prevalence of allergic disorders such as allergic rhinitis in the region. Technavio’s market research analysts estimate the ENT disorder treatment market in APAC to account for a revenue of more than USD 4,289 million by 2021.
The leading vendors operating in the global ENT disorder treatment market are:
- ALK
- GSK
- Novartis
- Sanofi
Other prominent vendors in the market include Allergan, AstraZeneca, Dr. Reddy’s Laboratories, Lupin, Merck, Mylan, Otonomy, Pfizer, Sun Pharma, and Teva Pharmaceuticals.
A more detailed analysis is available in the Technavio report titled, ‘Global ENT Disorder Treatment Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Swine Health Market 2017-2021
- Global Botanical and Plant-Derived Drugs Market 2017-2021
- Global Therapeutic Drug Monitoring Market 2017-2021
To read more press releases – click here
